Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA7 | P43166 | 4/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269407 | 0.88 | CTSB (0.39) | HTTKDM4ELMNAALDH1A1NPC1 | |
| SCHEMBL30984085 | 0.81 | PSMB1 (0.43) | HTTKDM4ESMN1; SMN2LMNAEGFR | |
| SCHEMBL30983876 | 0.81 | HTT (0.59) | HTTCA1CA2CA7CA13 | |
| SCHEMBL30983969 | 0.78 | ALDH1A1 (0.34) | HTTCA1CA2CA7CA13 | |
| SCHEMBL5033956 | 0.78 | HTT (0.52) | HTTCA1CA2CA7CA13 | |
| SCHEMBL30984080 | 0.74 | CA1 (0.42) | HTTCA1CA2CA7CA13 | |
| SCHEMBL4743191 | 0.74 | HTT (0.61) | HTTCA1CA2CA7CA13 | |
| SCHEMBL8562625 | 0.73 | HTT (0.67) | HTTCA1CA2CA7CA13 | |
| SCHEMBL6277448 | 0.73 | HTT (0.60) | HTTCA1CA2CA7CA13 | |
| SCHEMBL30983985 | 0.73 | CTSB (0.43) | MAPTKDM4EPOLBLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | HTT 2747/4885CA1 3598/4885CA2 3019/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | HTT 2747/4885CA1 3598/4885CA2 3019/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | HTT 2747/4885CA1 3598/4885CA2 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.